Skip to main content
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD logo

ANHUI FENGYUAN PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 000153 ISIN · CNE0000014X5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,593 across all filing types
Latest filing 2026-05-26 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000153

About ANHUI FENGYUAN PHARMACEUTICAL CO., LTD

https://www.bbcayy.com

Anhui Fengyuan Pharmaceutical Co., Ltd. focuses on the research, development, and production of diverse medicinal products. Its core portfolio encompasses large-volume parenteral solutions, small-volume injections, and solid dosage forms including tablets, capsules, and granules. The company operates across multiple therapeutic categories, such as cardiovascular, anti-infective, digestive, and respiratory health. Beyond finished formulations, it manufactures active pharmaceutical ingredients (APIs) and nutritional supplements. The organization maintains an integrated production model, leveraging large-scale manufacturing facilities to supply essential healthcare products. Its operations emphasize quality control and technical innovation in the formulation of both generic and specialized medications.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions and voting results from the company’s 2025 Annual General Meeting, detailing each proposal’s vote counts and percentages. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-26 Chinese
安徽径桥律师事务所关于安徽丰原药业股份有限公司2025年度股东会法律意见书
AGM Information Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm in connection with the company’s 2025 Annual General Meeting (AGM), covering meeting convening, attendance, voting procedures and results, and concluding on legal compliance. It is part of the AGM materials rather than an annual report, earnings release, or standalone vote result announcement. Therefore, it fits the category for AGM Information (materials provided for an AGM).
2026-05-26 Chinese
关于召开2025年度业绩说明会的公告
Regulatory Filings Classification · 82% confidence The document is an investor notice announcing the date, time, and participation methods for the company’s 2025 online performance explanation meeting. It contains no financial statements or substantive presentation materials, nor is it a transcript or slide deck. It is a general regulatory announcement of an upcoming event and does not fit into specialized report categories (e.g., Annual Report, Interim Report, Investor Presentation). Therefore, it is classified under the fallback category Regulatory Filings (RNS).
2026-05-18 Chinese
关于全资子公司获得富马酸伏诺拉生化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 87% confidence The document is a corporate announcement (公告) that the company’s subsidiary has received regulatory approval for a new chemical raw material drug. It contains no financial statements, earnings figures, or meeting materials. It represents a general regulatory/compliance notice and does not fit specialized categories (e.g., earnings release, interim report). Therefore, it is best classified under Regulatory Filings (RNS).
2026-05-12 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, and potential impact on the company. There is no financial data, no mention of financial results, no regulatory filings related to financial reporting, no management or board changes, no voting results, no capital or financing updates, and no legal proceedings. The document is an official announcement about a regulatory approval related to the company's product line. It is not a report, transcript, or financial filing. Given the content and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-05-07 Chinese
丰原药业2025年度内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by an accounting firm and addresses the effectiveness of internal controls over financial reporting for the fiscal year ending December 31, 2025. The content includes auditor responsibilities, management responsibilities, inherent limitations of internal control, and an audit opinion on the effectiveness of internal controls. It also highlights specific issues related to guarantees and related party transactions. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other type of filing. The length is about 1043 characters, which is consistent with a standalone audit report rather than a brief announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2025
2026-04-28 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.